Show simple item record

dc.contributor.authorGuo, Dongsheng
dc.contributor.authorDaman, Katelyn
dc.contributor.authorDurso, Danielle Fernandes
dc.contributor.authorYan, Jing
dc.contributor.authorEmerson, Charles P. Jr.
dc.date.accessioned2022-11-29T15:50:47Z
dc.date.available2022-11-29T15:50:47Z
dc.date.issued2022-09-05
dc.identifier.citationGuo D, Daman K, Durso DF, Yan J, Emerson CP. Generation of iMyoblasts from Human Induced Pluripotent Stem Cells. Bio Protoc. 2022 Sep 5;12(17):e4500. doi: 10.21769/BioProtoc.4500. PMID: 36213105; PMCID: PMC9501722.en_US
dc.identifier.eissn2331-8325
dc.identifier.doi10.21769/BioProtoc.4500en_US
dc.identifier.pmid36213105
dc.identifier.urihttp://hdl.handle.net/20.500.14038/51348
dc.description.abstractSkeletal muscle stem cells differentiated from human-induced pluripotent stem cells (hiPSCs) serve as a uniquely promising model system for investigating human myogenesis and disease pathogenesis, and for the development of gene editing and regenerative stem cell therapies. Here, we present an effective and reproducible transgene-free protocol for derivation of human skeletal muscle stem cells, iMyoblasts, from hiPSCs. Our two-step protocol consists of 1) small molecule-based differentiation of hiPSCs into myocytes, and 2) stimulation of differentiated myocytes with growth factor-rich medium to activate the proliferation of undifferentiated reserve cells, for expansion and cell line establishment. iMyoblasts are PAX3 + /MyoD1 + myogenic stem cells with dual potential to undergo muscle differentiation and to self-renew as a regenerative cell population for muscle regeneration both ex vivo and in vivo . The simplicity and robustness of iMyoblast generation and expansion have enabled their application to model the molecular pathogenesis of Facioscapulohumeral Muscular Dystrophy and Limb-Girdle Muscular Dystrophies, to both ex vivo and in vivo muscle xenografts, and to respond efficiently to gene editing, enabling the co-development of gene correction and stem cell regenerative therapeutic technologies for the treatment of muscular dystrophies and muscle injury. Graphical abstract.en_US
dc.language.isoenen_US
dc.relation.ispartofBio-protocolen_US
dc.relation.urlhttps://doi.org/10.21769/bioprotoc.4500en_US
dc.rightsCopyright © Guo et al. This article is distributed under the terms of the Creative Commons Attribution License (CC BY 4.0).en_US
dc.subjectDifferentiationen_US
dc.subjectHuman induced pluripotent stem cells (hiPSCs)en_US
dc.subjectMuscular dystrophyen_US
dc.subjectMyogenesisen_US
dc.subjectReserve cellen_US
dc.subjectiMyoblasten_US
dc.titleGeneration of iMyoblasts from Human Induced Pluripotent Stem Cellsen_US
dc.typeJournal Articleen_US
dc.source.journaltitleBio-protocol
dc.source.volume12
dc.source.issue17
dc.source.countryUnited States
dc.identifier.journalBio-protocol
refterms.dateFOA2022-11-29T15:50:47Z
dc.contributor.departmentLi Weibo Institute for Rare Diseases Researchen_US
dc.contributor.departmentNeurologyen_US
dc.contributor.departmentWellstone Center for FSHDen_US


Files in this item

Thumbnail
Name:
Bio-protocol4500.pdf
Size:
709.3Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record